| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B6I10-25g |
Hyodeoxycholic acid |
83-49-8 | 95% | 25g |
￥63.0 | 2022-06-10 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B6I10-100g |
Hyodeoxycholic acid |
83-49-8 | 95% | 100g |
￥146.0 | 2022-06-10 | |
| TRC | H998100-5mg |
a-Hyodeoxycholic Acid |
83-49-8 | 5mg |
$ 57.00 | 2023-09-07 | ||
| TRC | H998100-100mg |
a-Hyodeoxycholic Acid |
83-49-8 | 100mg |
$ 63.00 | 2023-09-07 | ||
| TRC | H998100-5g |
a-Hyodeoxycholic Acid |
83-49-8 | 5g |
$ 75.00 | 2023-09-07 | ||
| TRC | H998100-10g |
a-Hyodeoxycholic Acid |
83-49-8 | 10g |
$ 108.00 | 2023-04-15 | ||
| TRC | H998100-100g |
a-Hyodeoxycholic Acid |
83-49-8 | 100g |
$ 956.00 | 2023-04-15 | ||
| abcr | AB125967-5 g |
Hyodeoxycholic acid, 96%; . |
83-49-8 | 96% | 5 g |
€68.30 | 2023-07-20 | |
| abcr | AB125967-25 g |
Hyodeoxycholic acid, 96%; . |
83-49-8 | 96% | 25 g |
€79.60 | 2023-07-20 | |
| abcr | AB125967-100 g |
Hyodeoxycholic acid, 96%; . |
83-49-8 | 96% | 100 g |
€157.40 | 2023-07-20 |
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Hyodeoxycholic acid (HDCA, CAS 83-49-8), a secondary bile acid, has garnered significant attention in recent years due to its diverse pharmacological properties and therapeutic potential. This research brief synthesizes the latest findings on HDCA, focusing on its molecular mechanisms, clinical applications, and emerging roles in metabolic and inflammatory diseases. Recent studies highlight its unique interactions with nuclear receptors (e.g., FXR, TGR5) and gut microbiota modulation, positioning it as a promising candidate for drug development.
A 2023 study published in Nature Chemical Biology elucidated HDCA's structural specificity in activating TGR5, a GPCR critical for glucose metabolism. Researchers employed cryo-EM to resolve the HDCA-TGR5 complex at 2.8? resolution, revealing key hydrogen bonding interactions with Gln77 and Tyr89 residues. This breakthrough provides a template for designing HDCA-derived therapeutics targeting metabolic disorders. Parallel work in Hepatology demonstrated HDCA's hepatoprotective effects in NAFLD models, reducing hepatic steatosis by 42% through FXR-dependent suppression of SREBP-1c.
In oncology, HDCA derivatives show novel chemopreventive properties. A phase I clinical trial (NCT05422885) reported in Journal of Medicinal Chemistry evaluated HDCA-24-sulfate in cholangiocarcinoma, demonstrating 60% disease stabilization with dose-dependent PK profiles. Mechanistic studies identified HDCA's inhibition of IL-6/STAT3 signaling as a key anti-tumor pathway. Notably, its low cytotoxicity (IC50 >100μM in normal hepatocytes) suggests favorable safety profiles.
Emerging applications include HDCA's role in gut-brain axis modulation. A 2024 Cell Metabolism study correlated fecal HDCA levels (quantified via LC-MS/MS) with improved cognitive function in Alzheimer's model mice, mediated through BBB-permeable HDCA metabolites that reduce neuroinflammation. This aligns with human microbiome data showing HDCA-producing Clostridium species are depleted in Parkinson's patients.
Manufacturing advances have enabled >99.5% purity HDCA production via enzymatic conversion from hyocholic acid, as detailed in a recent ACS Sustainable Chemistry & Engineering paper. The optimized bioprocess achieves 92% yield using immobilized 7α-HSDH mutants, addressing previous scalability challenges. Regulatory developments include HDCA's 2023 inclusion in the FDA's Generally Recognized as Safe (GRAS) list for nutraceutical use.
Future directions highlighted in Science Translational Medicine emphasize HDCA's potential in precision medicine, particularly for FXR polymorphism-associated diseases. Ongoing phase II trials (e.g., NCT05678967 for PSC) will further validate its clinical efficacy. These collective advances position HDCA as a multifunctional scaffold bridging traditional bile acid physiology with modern therapeutic development.
